Atogepant and Sumatriptan: No Clinically Relevant Drug–Drug Interactions in a Randomized, Open-Label, Crossover Trial

References

• Pietrobon D , MoskowitzMA. Pathophysiology of migraine. Annu. Rev. Physiol.75, 365–391 (2013).
   PubMed Web of Science ®Google Scholar
• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet392(10159), 1789–1858 (2018).
   PubMed Web of Science ®Google Scholar
• Lipton RB , BigalME , DiamondM , FreitagF , ReedML , StewartWF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68(5), 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• GBD 2016 Headache Collaborators . Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol.17(11), 954–976 (2018).
   PubMed Web of Science ®Google Scholar
• Lipton RB , ManackAdams A , BuseDC , FanningKM , ReedML. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache56(8), 1280–1289 (2016).
   PubMed Web of Science ®Google Scholar
• Lew C, Punnapuzha S. Migraine medications. StatPearls Publishing LLC, FL, USA (2020).
   Google Scholar
• Becker WJ . Acute migraine treatment in adults. Headache55(6), 778–793 (2015).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , RoonKI , LiptonRB , GoadsbyPJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Iyengar S , OssipovMH , JohnsonKW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain158(4), 543–559 (2017).
   PubMed Web of Science ®Google Scholar
• Edvinsson L . CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br. J. Clin. Pharmacol.80(2), 193–199 (2015).
   PubMed Web of Science ®Google Scholar
• Charles A , Pozo-RosichP. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet394(10210), 1765–1774 (2019).
   PubMed Web of Science ®Google Scholar
• Dodick DW . CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia39(3), 445–458 (2019).
   PubMed Web of Science ®Google Scholar
• Source: AbbVie . FDA approves QULIPTA (atogepant), the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine (2021). https://news.abbvie.com/news/press-releases/fda-approves-qulipta-atogepant-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-preventive-treatment-migraine.htm
   Google Scholar
• Goadsby PJ , DodickDW , AilaniJet al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised Phase 2b/3 trial. Lancet Neurol.19(9), 727–737 (2020).
   PubMed Web of Science ®Google Scholar
• Martelletti P . Combination therapy in migraine: asset or issue?Expert Rev. Neurother.20(10), 995–996 (2020).
   PubMed Web of Science ®Google Scholar
• Borro M , GuglielmettiM , SimmacoM , MartellettiP , GentileG. The future of pharmacogenetics in the treatment of migraine. Pharmacogenomics20(16), 1159–1173 (2019).
   PubMed Web of Science ®Google Scholar
• Lionetto L , BorroM , CurtoMet al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert. Opin. Drug. Metab. Toxicol.12(4), 399–406 (2016).
   PubMed Web of Science ®Google Scholar
• Martelletti P , CipollaF , CapiM , CurtoM , LionettoL. Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, preventive treatment of migraine. Drugs Future45(5), 285 (2020).
   Web of Science ®Google Scholar
• Martelletti P , LucianiM , SpuntarelliV , BentivegnaE. Deprescribing in migraine. Expert Opin. Drug Saf.20(6), 623–625 (2021).
   PubMed Web of Science ®Google Scholar
• Matthaei J , KuronD , FaltracoFet al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin. Pharmacol. Ther.99(6), 633–641 (2016).
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration . Clinical drug interaction studies – study design, data analysis, and clinical implications guidance for industry. (2017).
   Google Scholar
• US Food & Drug Administration . Guidance for industry drug-induced liver injury: premarketing clinical evaluation (2009). www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation
   Google Scholar
• Sakamoto Y , SekinoY , YamadaEet al. Effect of sumatriptan on gastric emptying: a crossover study using the BreathID system. World J. Gastroenterol.18(26), 3415–3419 (2012).
   PubMed Web of Science ®Google Scholar
• Boinpally R , JakateA , ButlerM , BorbridgeL , PericlouA. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase I trial. Clin. Pharmacol. Drug Development doi:10.1002/cpdd.916 (2021).
   Web of Science ®Google Scholar
• Boinpally R , SpaventaJ , ChenK , ButlerM. Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: a randomized trial. Clin. Drug Investig.41(6), 557–567 (2021).
   PubMed Web of Science ®Google Scholar
• Ankrom W , XuJ , ValleeMHet al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female participants. J. Clin. Pharmacol.60(9), 1157–1165 (2020).
   PubMed Web of Science ®Google Scholar
• Min KC , KraftWK , BondiskeyPet al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthly adults. Clin. Transl. Sci.14(2), 599–605 (2021).
   PubMed Web of Science ®Google Scholar
• Scott AK . Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet.27(5), 337–344 (1994).
   PubMed Web of Science ®Google Scholar
• Imitrex [package insert]. GlaxoSmithKline, NC, USA (2017).
   Google Scholar
• Scott AK , WalleyT , BreckenridgeAM , LaceyLF , FowlerPA. Lack of an interaction between propranolol and sumatriptan. Br. J. Clin. Pharmacol.32(5), 581–584 (1991).
   PubMed Web of Science ®Google Scholar
• Van Hecken AM , DepréM , DeSchepper PJ , FowlerPA , LaceyLF , DurhamJM. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br. J. Clin. Pharmacol.34(1), 82–84 (1992).
   PubMed Web of Science ®Google Scholar
• Duquesnoy C , MametJP , SumnerD , FuseauE. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci.6(2), 99–104 (1998).
   PubMed Web of Science ®Google Scholar
• Moore KH , LeesePT , McNealSet al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin. Ther.24(4), 583–594 (2002).
   PubMed Web of Science ®Google Scholar
• Moore KH , McNealS , BrittoMR , ByeC , SaleM , RichardsonMS. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers. Clin. Ther.24(11), 1887–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Ailani J , LiptonRB , GoadsbyPJet al. Atogepant for the preventive treatment of migraine.. N. Engl. J. Med.385(8), 695–706 (2021).
   PubMed Web of Science ®Google Scholar
• Burch RC , BuseDC , LiptonRB. Migraine: epidemiology, burden, and comorbidity. Neurol. Clin.37(4), 631–649 (2019).
   PubMed Web of Science ®Google Scholar